Page 1

ZurRose Group Frauenfeld , 21 October 2021 Press release Ad hoc announcement pursuant to Art . 53 LR Zur Rose Group continues to grow strongly - - Growth continues : revenue up 17.7 per cent in the first nine months of 2021 France expands by extending product range to include OTC medications DocMorris healthcare platform takes next step in its development Zur Rose expects external revenue growth of over 15 per cent for the full year In a challenging market environment the Zur Rose Group posted significant growth in the first nine months of 2021. External revenue¹ increased by 17.7 per cent in local currency terms or 19.7 per cent in Group currency terms to CHF 1,490.8 million . Growth in the third quarter 2021 was 11.9 per cent year - on - year in local currency terms . The number of active customers rose by 400,000 to 12.1 million in the third quarter.² Significant revenue growth in all markets The Zur Rose Group saw powerful growth in Germany in the first nine months , with external reve- nue up by 24.9 per cent in local currency terms . The increase is mainly due to the online business in non - prescription drugs and healthcare products , which more than made up for the slight decline in revenue from prescription drugs on a paper prescription . In the Swiss home market Zur Rose grew at a consistently stable 5.3 per cent , which is ahead of the market . The Europe segment reported a pleasing revenue growth with a plus of 20.2 per cent in local currency terms . DocMorris.fr extends range to include OTC medications DoctiPharma.fr , now DocMorris.fr , the second - largest online pharmaceutical platform in France and part of the largest marketplace in Europe , is extending its product range with a strategic partner in November 2021 to include OTC medications . This will provide customers in France with easy and safe access to a broad range of health products and pharmaceutical advice . The considerably in- creased customer traffic will also make the platform more attractive for pharmacy partners . As part of this expansion the DoctiPharma brand has been changed to DocMorris , the umbrella brand of the Zur Rose Group for the European healthcare ecosystem . The improved brand identity and ser- vices offered are being accompanied by a multimedia campaign . The intention is to extend the ser- vice offering at a later stage through a partnership in telemedicine . DocMorris healthcare platform in Germany takes next step in its development Thanks to the integration of the DocMorris Express marketplace with its network of partner phar- macies and their services , customers of the healthcare platform can now enjoy both mail order and the option of same day express delivery by a local partner pharmacy when ordering medications 2 1 External revenue consists of the consolidated revenue of the Zur Rose Group plus the mail - order revenue of pharmacies supplied by the Zur Rose Group , less the consolidated revenue for their supply . Customers supplied by the Zur Rose Group , either directly or through its partners . Zur Rose Group AG Walzmühlestrasse 60 8500 Frauenfeld Switzerland T +41 52 724 00 20 info@zurrose.com zurrosegroup.com